December 12, 2025
After lacklustre years the biotech markets have been waiting for a positive indicative signal, and we likely just received it.
On December 9, 2025, the biotech industry recorded its single best day for follow-on offerings in history. In a span of just 24 hours, eight companies raised a staggering $3.2 billion, with seven of the eight deals being upsized due to overwhelming demand.
This wasn’t just a flurry of activity; it was a statement. After years of a “biotech winter” and a cautious recovery, institutional capital is being deployed into high-quality assets. For industry observers and private companies eyeing the public markets, this record-breaking day offers a critical roadmap for what to expect in the 2026 IPO window.
The “Class of Dec 9”: Data is the Currency
The most striking feature of this fundraising surge was its catalyst: robust clinical data. The market has moved past the “promising platform” phase of 2020-2021 and settled firmly into a “show me the data” paradigm.
Nearly every company that successfully raised capital did so immediately following a major clinical or regulatory de-risking event:
- Obesity & Metabolism: Structure Therapeutics ($650M) and Wave Life Sciences ($350M) capitalized on the insatiable appetite for next-gen weight loss treatments. Structure leveraged positive Phase 2b data for its oral GLP-1, while Wave surged on Phase 1 data showing its RNA-based approach could rival current standards while preserving muscle mass.
- Targeted Degradation & Oncology: Kymera Therapeutics raised $602M following remarkable Phase 1b data for its protein degrader in inflammatory conditions. Terns Pharmaceuticals secured $650M after posting strong results in chronic myeloid leukemia.
- Rare Disease & Regulatory Wins: Dyne Therapeutics ($350M) and Vera Therapeutics ($261M) raised funds on the back of pivotal regulatory progress—Dyne moving toward FDA approval in Duchenne muscular dystrophy and Vera following its BLA submission for IgA nephropathy.
Why This Matters for 2026
Historically, a robust follow-on market acts as the primer for a healthy IPO market. Public investors typically need to feel comfortable refinancing existing public portfolios before they take on the risk of new private listings.
The ability of the market to absorb $3.2 billion in a single day—and ask for more—signals that the buyer’s appetite is recovering even prior to FED rate cuts.
Here is what our take is on the implications for the year ahead:
- The Window is Opening, But the Bar is High
The “Class of 2026” IPO candidates will need to resemble traits of the “Class of Dec 9.” The market is rewarding companies with clinical validation (Phase 2 or robust Phase 1b data), differentiated mechanisms, and clear regulatory paths. The era of preclinical IPOs remains largely closed; investors are paying for more de-risked assets.
- Macro Tailwinds are Aligning
The timing of this surge is no accident. With the Federal Reserve signalling a clear trajectory for interest rate cuts in 2026, the cost of capital is falling. This creates a “risk-on” environment where growth-focused Biotechs become attractive again compared to safer assets.
- M&A Provides the Floor
This capital injection comes against a backdrop of robust M&A activity, with big pharma continuing to pay premiums for late-stage assets. This gives investors confidence that if a quality biotech doesn’t go to the market alone, it remains a prime acquisition target.
The Conclusion
The $3.2 billion day confirms that the market has transitioned from survival mode to growth mode. For private companies sitting in the backlog, the water is finally warm enough to jump in—provided they bring the data to back it up. We expect a busy Q1/2 2026 of “testing the waters,” leading to a normalized, high-quality IPO calendar by mid-year.